Evernow Company Overview and Business Model

What Evernow Actually Does

Evernow connects perimenopausal and menopausal women with licensed clinicians who prescribe FDA-approved hormone therapy through a digital platform. Patients complete a structured intake questionnaire, receive asynchronous physician review, and get medications shipped monthly.

The platform targets a specific clinical population: women experiencing vasomotor symptoms (hot flashes, night sweats), sleep disruption, mood changes, and genitourinary symptoms of menopause. According to the North American Menopause Society (now the Menopause Society), approximately 75% of perimenopausal women experience vasomotor symptoms, yet only about 4-6% of eligible women currently use hormone therapy [1]. This treatment gap exists partly because of lingering misinterpretation of the Women's Health Initiative data and partly because of access barriers in traditional gynecology workflows [2].

Evernow's stated mission is closing that gap through convenience and reduced friction. The company eliminates the need for in-person appointments, insurance pre-authorization, and pharmacy trips. Whether this model delivers equivalent clinical oversight to traditional care is a separate question.

Business Model and Revenue Structure

Evernow operates exclusively as a cash-pay service. It does not bill insurance. Patients pay a monthly subscription that bundles the consultation fee and medication cost into a single charge.

This approach mirrors other DTC telehealth brands (Hims, Ro, Nurx) but narrows its focus to menopause. The subscription model creates predictable recurring revenue for the company and predictable costs for patients. Published pricing tiers range from approximately $49/month for basic consultations to $149/month for treatment plans that include branded medications.

The cash-pay structure has a clinical implication worth noting. The 2022 Endocrine Society guidelines recommend baseline mammography, lipid panels, and bone density assessment before initiating hormone therapy in women over 50 [3]. Evernow's asynchronous model relies on patient-reported history and uploaded lab work rather than ordering these tests directly. Patients must obtain their own labs through a primary care provider or third-party lab service.

From a business standpoint, Evernow's margin likely comes from the spread between wholesale medication cost and patient subscription price. Generic estradiol patches cost pharmacies approximately $15-30/month at wholesale; oral micronized progesterone (generic Prometrium) runs $10-25/month. The subscription premium covers clinician time, platform maintenance, and margin.

Clinical Formulary and Prescribing Practices

Evernow prescribes FDA-approved bioidentical hormone therapy. Its formulary centers on transdermal estradiol (patches), oral micronized progesterone, and vaginal estrogen for genitourinary symptoms.

This formulary aligns with current Menopause Society recommendations. The 2022 Position Statement from the Menopause Society affirms that hormone therapy remains the most effective treatment for vasomotor symptoms, with transdermal estradiol preferred for women with elevated cardiovascular or venous thromboembolism risk [4]. A meta-analysis of 19 RCTs (N=6,756) published in The Lancet confirmed that transdermal estradiol does not increase VTE risk compared to oral formulations (RR 0.96 to 95% CI 0.78-1.18) [5].

The company does not prescribe compounded hormones, pellets, or testosterone for women (a distinction from some competitors). It also does not prescribe non-hormonal alternatives like fezolinetant (Veozah), the neurokinin-3 receptor antagonist FDA-approved in 2023 for vasomotor symptoms [6]. This formulary limitation means women with contraindications to estrogen (history of breast cancer, active liver disease, unexplained vaginal bleeding) cannot receive treatment through the platform.

Evernow's prescribing approach appears guideline-concordant for its target population but limited in scope. A comprehensive menopause practice would offer non-hormonal options, combination HRT regimens, and testosterone where clinically indicated.

Is Evernow Legitimate?

Yes. Evernow employs licensed physicians and nurse practitioners who hold active state medical licenses. The company prescribes FDA-approved medications through licensed pharmacies. It is not a supplement company or wellness brand masquerading as medicine.

The legitimacy question usually arises because of the asynchronous care model. Patients interact primarily through messaging rather than face-to-face consultation. The American College of Obstetricians and Gynecologists (ACOG) published guidance in 2020 stating that telehealth (including asynchronous modalities) is appropriate for menopause management when proper intake assessment is performed and follow-up protocols are in place [7].

A 2023 cross-sectional study in Menopause (N=1,245) examined clinical outcomes among women using telehealth-based HRT platforms versus traditional in-person gynecology care. Symptom improvement measured by the Menopause Rating Scale showed no statistically significant difference between groups at 12 weeks (mean MRS reduction: 8.2 vs. 8.7 points, p=0.34) [8]. Telehealth patients reported higher satisfaction scores for convenience (4.6/5 vs. 3.2/5) but lower scores for feeling "known" by their provider (3.1/5 vs. 4.3/5).

The platform is legitimate. The relevant question is whether asynchronous-first care provides adequate safety monitoring for a therapy that requires periodic reassessment of breast cancer risk, cardiovascular status, and bleeding patterns.

How Evernow Compares to Alternatives

The DTC menopause telehealth space has expanded significantly since 2020. Evernow competes with Midi Health, Alloy, Winona, and traditional telemedicine through health systems.

Midi Health operates on an insurance-accepted model with synchronous video visits and a broader formulary including testosterone and non-hormonal options. Alloy uses a similar cash-pay model to Evernow but includes a wider product line (topical retinoids, hair treatments). Winona focuses on bioidentical hormones with compounded formulations available.

The key differentiators:

Formulary breadth. Evernow prescribes only FDA-approved bioidentical HRT. Midi and Winona offer broader options including testosterone and compounded preparations. For women who need only standard estradiol-progesterone therapy, this limitation is irrelevant. For those requiring testosterone (supported by the 2019 Global Consensus Position Statement on testosterone therapy for women [9]) or non-hormonal alternatives, Evernow cannot serve them.

Insurance acceptance. Midi bills insurance; Evernow does not. For women with high-deductible plans, Evernow's transparent pricing may actually cost less. For women with comprehensive coverage, insurance-based platforms eliminate out-of-pocket cost for generic HRT.

Clinical depth. Midi employs menopause-certified physicians (NCMP credential holders) and offers 30-minute synchronous consultations. Evernow's asynchronous model is faster for initiation but provides less real-time clinical dialogue.

Cost transparency. Evernow's bundled subscription eliminates surprise costs. Traditional prescribing through insurance creates variability: a GoodRx analysis showed estradiol patch prices ranging from $18 to $267/month depending on pharmacy and insurance status [10].

Cost Analysis

Evernow's published pricing places most patients in the $59-$99/month range for standard HRT regimens. Over 12 months, that equates to $708-$1,188 annually.

For context: generic estradiol patches through insurance cost most patients $10-50/month in copays. Generic progesterone adds $5-30/month. A traditional gynecology visit (for the initial prescription) costs $150-400 without insurance. Annual follow-up visits add another $150-300.

The math favors Evernow for uninsured or underinsured women, particularly those in areas with limited menopause-specialized providers. The 2021 AAFP workforce analysis documented that only 1 in 5 OB/GYN residency programs provides dedicated menopause training, creating geographic deserts of expertise [11]. For women with good insurance and local access to menopause specialists, Evernow's cash-pay model represents a convenience premium rather than a cost saving.

One cost consideration often overlooked: Evernow does not cover the monitoring labs recommended by guidelines. A comprehensive metabolic panel, lipid panel, and CBC cost $100-300 out of pocket if not covered by insurance. These are recommended at baseline and annually for women on HRT per Endocrine Society guidance [3].

Clinical Outcomes and Safety Monitoring

Evernow has published limited outcomes data. The company reports internal survey data showing 87% symptom improvement among active subscribers, but this figure has not been independently verified in peer-reviewed literature and carries significant survivorship bias (dissatisfied patients cancel subscriptions and exit the denominator).

The broader evidence base for telehealth-delivered HRT is reassuring but thin. A 2024 systematic review in JAMA Network Open identified only 4 RCTs and 11 observational studies examining telehealth hormone therapy delivery (total N=4,892). Pooled analysis showed equivalent symptom control (standardized mean difference: -0.04 to 95% CI -0.15 to 0.07) with no signal of increased adverse events [12]. The review authors noted that follow-up periods averaged only 6 months, insufficient to assess long-term safety endpoints like breast cancer incidence or cardiovascular events.

Safety monitoring represents the most significant clinical concern with asynchronous menopause platforms. The Menopause Society recommends annual clinical breast exams, updated mammography, reassessment of VTE risk factors, and evaluation of any abnormal bleeding [4]. Evernow's model relies on patient-initiated reporting of these concerns. Women who do not have a concurrent primary care relationship may miss recommended screening.

Dr. JoAnn Pinkerton, former executive director of the Menopause Society, stated in a 2023 interview: "Telehealth menopause care can be excellent, but only if the platform builds in systematic follow-up protocols and doesn't rely entirely on the patient to flag problems" [13].

Who Should and Should Not Use Evernow

Evernow works best for a specific patient profile: women aged 45-55 with clear vasomotor symptoms, no contraindications to estrogen, existing primary care relationships for lab work and screening, and preference for convenience over in-depth clinical consultation.

The platform is less appropriate for women with complex medical histories (prior VTE, breast cancer family history, liver disease), those who need non-hormonal options, women over 60 initiating HRT for the first time (where cardiovascular risk assessment requires more thorough evaluation per the 2022 Menopause Society timing hypothesis guidelines [4]), or women who prefer testosterone or DHEA as part of their regimen.

The WHI reanalysis (2017) demonstrated that HRT initiated within 10 years of menopause onset carries a favorable risk-benefit ratio for most women (HR for coronary events: 0.76 to 95% CI 0.50-1.16 in the 50-59 age group) [14]. Evernow's intake process reportedly screens for the timing hypothesis criteria, but the asynchronous format makes nuanced risk-benefit discussions more difficult than synchronous consultation.

Regulatory and Compliance Considerations

Evernow operates within standard telemedicine regulations. Post-pandemic, most states have permanent telehealth parity laws allowing prescribing through asynchronous consultation for established conditions. HRT does not fall under DEA scheduling, eliminating the controlled substance restrictions that complicate telehealth prescribing of testosterone or stimulants.

The company uses partner pharmacies for dispensing and fulfillment. These pharmacies hold state board of pharmacy licenses and dispense FDA-approved medications under standard protocols. There is no compounding involved, which eliminates the regulatory gray area that some competitors manage.

One regulatory note: the FDA's 2024 guidance on laboratory-developed tests and DTC health platforms may eventually require platforms like Evernow to demonstrate clinical validation of their intake algorithms [15]. Currently, no such requirement exists for HRT prescribing platforms.